Description du projet
Gestion du diabète: vers des données réelles
Les essais cliniques sont considérés comme la référence absolue pour étudier l’innocuité et l’efficacité des médicaments ou des interventions thérapeutiques. Cependant, les données du monde réel (RWD pour «real-world data») qui sont régulièrement recueillies à partir de diverses sources telles que les appareils, les dispositifs portables et les dossiers médicaux électroniques, gagnent du terrain. Le projet REDDIE, financé par l’UE, se donne pour objectif de soutenir l’utilisation des RWD pour la gestion du diabète sucré, une maladie chronique qui affecte des millions de personnes dans le monde. Le consortium s’appuiera sur les données des registres nationaux pour évaluer les résultats d’interventions spécifiques. Il établira en outre des normes pour l’acceptation et la mise en œuvre des RWD dans le processus d’évaluation des médicaments et d’autres interventions relatives à la prévention et au traitement du diabète.
Objectif
Randomised controlled trials are the cornerstone of evidence-based medicine. However, the digitisation of real-world data (RWD) including data from devices, wearables, and electronic health records in large national registries provides opportunities to demonstrate efficacy and safety of innovative technologies including drugs, devices, diagnostics, and digital health. These data are particularly relevant to long-term conditions such as diabetes mellitus, where drugs, lifestyle interventions, and digital technologies often work together. To better utilise RWD in diabetes for regulatory decision making, a development of standards, guidance, and an assessment of the efficacy to effectiveness gap is needed.
REDDIE (Real-World Evidence for Decisions in Diabetes) aims to explore how RWD can complement RCTs to improve efficacy, safety, and value for money of technologies to prevent and treat diabetes. The overall aim of REDDIE is to support the use of RWD in diabetes and health-related research, which will maximise Europe’s scientific expertise and know-how to benefit people with diabetes, resulting in safer, more efficient, and cost-effective interventions.
We thus aim to engage with stakeholders such as regulatory and HTA authorities and co-develop evidentiary standards for the collection, assessment, and acceptability of RWD. We will then develop and validate state-of-the art modelling techniques using synthetic data derived from large national registries to better assess outcomes of interventions using RWD. We will use data from four large national registries to elucidate the gap between outcomes in RCTs and RWD studies, and understand the factors that affect this gap. Finally, we will test the ability of machine learning to facilitate the better use of RWD.
REDDIE will generate standards for RWD use for the evaluation of medicines and other interventions by regulatory authorities and HTA bodies.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
8010 Graz
Autriche